Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Anxiety Disorders 2 Weight Loss 1 Recurrence 1 Lung Neoplasms 1 Glioma 1 Fatigue 1 Depression 1 Colorectal Adenocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Cachexia 1 Brain Neoplasms 1 Advanced Cancer 1 Adenocarcinoma of Lung 1

Interventions

Nivolumab 20 Ipilimumab 10 Surveys and Questionnaires 7 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Interviews as Topic 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × Fluoxetine × Clear all

NCT00512291 2011-09-27

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

M.D. Anderson Cancer Center

Phase NA Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡